Shares of GlaxoSmithKline plc (LON:GSK) fell 0% during mid-day trading on Tuesday . The company traded as low as GBX 1,343 ($18.21) and last traded at GBX 1,346.80 ($18.26). 8,370,000 shares were traded during trading, a decline of 4% from the average session volume of 8,680,000 shares. The stock had previously closed at GBX 1,346.80 ($18.26).
A number of research firms have recently issued reports on GSK. JPMorgan Chase & Co. restated a “neutral” rating and set a GBX 1,570 ($21.29) price objective on shares of GlaxoSmithKline in a research report on Monday, October 2nd. Liberum Capital restated a “buy” rating and set a GBX 1,760 ($23.87) price objective on shares of GlaxoSmithKline in a research report on Wednesday, October 25th. Beaufort Securities restated a “buy” rating and set a GBX 1,800 ($24.41) price objective on shares of GlaxoSmithKline in a research report on Monday, October 23rd. Shore Capital restated a “hold” rating on shares of GlaxoSmithKline in a research report on Wednesday, September 20th. Finally, UBS Group upgraded GlaxoSmithKline to a “buy” rating and set a GBX 1,550 ($21.02) price objective on the stock in a research report on Monday, November 27th. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company. GlaxoSmithKline has a consensus rating of “Hold” and a consensus target price of GBX 1,555.24 ($21.09).
The firm has a market capitalization of $65,990.00 and a P/E ratio of 2,768.75.
The firm also recently disclosed a dividend, which will be paid on Thursday, January 11th. Shareholders of record on Thursday, November 9th will be paid a GBX 19 ($0.26) dividend. This represents a yield of 1.41%. The ex-dividend date of this dividend is Thursday, November 9th.
In other GlaxoSmithKline news, insider Urs Rohner acquired 473 shares of GlaxoSmithKline stock in a transaction on Wednesday, October 25th. The shares were bought at an average price of GBX 1,518 ($20.59) per share, with a total value of £7,180.14 ($9,737.10). Also, insider Patrick Vallance sold 20,000 shares of the business’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of GBX 1,310 ($17.77), for a total value of £262,000 ($355,302.41). In the last three months, insiders acquired 492 shares of company stock worth $743,372.
COPYRIGHT VIOLATION WARNING: This story was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.com-unik.info/2018/01/11/glaxosmithkline-gsk-trading-down-0.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.